Molecular Partners Ag (NASDAQ: MOLN)
Molecular Partners Ag Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Molecular Partners Ag Company Info
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
News & Analysis
3 Stocks That Have Soared as the Market Sank: Are They Buys Now?
Two of them could be.
Why Molecular Partners Stock Crushed the Market Today
The company had some very good news to deliver about its coronavirus drug candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.